Investment Thesis
PSTV is a micro-revenue medical device company in acute financial distress, burning cash at 4x its annual revenue with only ~2.5 months of runway remaining. The company cannot cover operating expenses or debt service from operations, indicating a fundamentally broken business model requiring immediate capital injection or strategic restructuring to survive.
Strengths
- Maintains $4.3M cash reserve providing minimal operational runway
- Loss trajectory improved year-over-year with net loss declining 72.5%
- Operates in high-growth medical device sector with potential long-term tailwinds
Risks
- Catastrophic cash burn of -$20.8M annually against $5.2M revenue with <3 months liquidity runway
- Grossly inadequate gross margin of 7.9% indicating either severe pricing failure or near-total operational underutilization
- Cannot service debt obligations from operations with -250.8x interest coverage, forcing reliance on cash depletion
Key Metrics to Watch
- Monthly cash burn rate and projected cash depletion date
- Revenue inflection point and gross margin recovery trajectory
- Debt covenant compliance and refinancing/capital raise announcements
Financial Metrics
Revenue
5.2M
Net Income
-22.4M
EPS (Diluted)
$-0.29
Free Cash Flow
-20.8M
Total Assets
16.3M
Cash
4.3M
Profitability Ratios
Gross Margin
7.9%
Operating Margin
-293.5%
Net Margin
-429.4%
ROE
-560.2%
ROA
-137.1%
FCF Margin
-399.8%
Balance Sheet & Liquidity
Current Ratio
1.23x
Quick Ratio
1.22x
Debt/Equity
0.95x
Debt/Assets
75.5%
Interest Coverage
-250.79x
Long-term Debt
3.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T17:30:24.980955 |
Data as of: 2025-12-31 |
Powered by Claude AI